Skip to main content
Fig. 6 | Journal of Experimental & Clinical Cancer Research

Fig. 6

From: A novel PDPN antagonist peptide CY12-RP2 inhibits melanoma growth via Wnt/β-catenin and modulates the immune cells

Fig. 6

Influence of CY12-RP2 on the immune-mediated anti-tumor capacity of PBMC in vitro and in vivo. A The procedure of PBMC isolation from donor peripheral blood, and the ratio of different immune cells in PBMC was assayed by flow cytometry. B PBMCs were stimulated with CY12-RP2 for 48 h, and the cytokine levels in the supernatant were assayed by ELISA. C, D PBMCs stimulated by CY12-RP2 were co-cultured with melanoma cells to demonstrate its killing capacity (C), statistical analysis was performed for the killing capacity of PBMC (D). E Brightfield and fluorescent microscopy images of A375 cells (red) co-culture with PBMC (GFP) were stimulated with various concentrations (0, 2, 10, 50 μM) of CY12-RP2. Data are presented as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001 versus control

Back to article page